The Experts below are selected from a list of 303 Experts worldwide ranked by ideXlab platform

Rowan T Chlebowski - One of the best experts on this subject based on the ideXlab platform.

  • Breast Tenderness after initiation of conjugated equine estrogens and mammographic density change
    Breast Cancer Research and Treatment, 2012
    Co-Authors: Carolyn J Crandall, Aaron K Aragaki, Anne Mctiernan, Garnet L Anderson, Jean Wactawskiwende, Jane A Cauley, Joann E Manson, Rowan T Chlebowski
    Abstract:

    We examined the association between new-onset Breast Tenderness and change in mammographic density after initiation of conjugated equine estrogens (CEE). We analyzed baseline, year 1 and 2 data from 695 participants of the Women’s Health Initiative Estrogen + Progestin (daily CEE 0.625 mg + medroxyprogesterone acetate 2.5 mg [MPA] or placebo) and Estrogen-Alone (CEE 0.625 mg or placebo) trials who participated in the Mammogram Density Ancillary Study. Using multivariable repeated measures models, we analyzed the association between new-onset Breast Tenderness (i.e. absence of baseline Tenderness and presence of Tenderness at year 1 follow-up) and change from baseline in percent mammographic density. Active therapy increased the odds of new-onset Breast Tenderness (CEE + MPA vs. placebo risk ratio [RR] 3.01, 95% confidence interval [95% CI] 1.96–4.62; CEE vs. placebo RR 1.70, 95% CI 1.14–2.53). Among women assigned to CEE + MPA, mean increase in mammographic density was greater among participants reporting new-onset of Breast Tenderness than among participants without new-onset Breast Tenderness (11.3 vs. 3.9% at year 1, 9.4 vs. 3.2% at year 2, P < 0.001). Among women assigned to CEE alone, increase in mammographic density at year 1 follow-up was not significantly different in women with new-onset Breast Tenderness compared to women without new-onset Breast Tenderness (2.4 vs. 0.6% at year 1, 2.2 vs. 1.0% at year 2, P = 0.30). The new-onset of Breast Tenderness after initiation of CEE + MPA, but not CEE alone, is associated with greater increases in mammographic density.

  • Breast Tenderness and Breast cancer risk in the estrogen plus progestin and estrogen alone women s health initiative clinical trials
    Breast Cancer Research and Treatment, 2012
    Co-Authors: Carolyn J Crandall, Aaron K Aragaki, Anne Mctiernan, Garnet L Anderson, Jane A Cauley, Joann E Manson, Rowan T Chlebowski
    Abstract:

    The associations between Breast Tenderness during use of conjugated equine estrogen (CEE) therapy with or without medroxyprogesterone (MPA) therapy and subsequent Breast cancer risk are unknown. We analyzed data from the Women’s Health Initiative Estrogen plus Progestin (N = 16,608, 5.6 years intervention) and estrogen-alone (N = 10,739, 6.8 years intervention) clinical trials until trial close-out (Spring 2005). At baseline and annually, participants underwent mammography and clinical Breast exam. Self-reported Breast Tenderness was assessed at baseline and 12 months. Invasive Breast cancer was confirmed by medical record review. The risk of new-onset Breast Tenderness after 12 months was significantly higher among women assigned to active therapy than placebo (CEE-alone vs. placebo risk ratio [RR] 2.15, 95% confidence interval [CI] 1.97–2.35; CEE + MPA vs. placebo RR 3.07, 95% CI 2.85–3.30). CEE + MPA doubled the risk of invasive Breast cancer among women with baseline Breast Tenderness (hazard ratio [HR] 2.16, 95% CI 1.29–3.74), but had a smaller effect among women without baseline Breast Tenderness (HR 1.17; 95% CI 0.97–1.41). New-onset Breast Tenderness was associated with a higher risk of Breast cancer among women assigned to CEE + MPA (HR 1.33, 95% CI 1.02–1.72, P = 0.03), but not among women assigned to CEE-alone (HR 0.98, 95% CI 0.62–1.53). New-onset Breast Tenderness during use of CEE + MPA was associated with increased subsequent Breast cancer risk. The association of CEE + MPA therapy with increased Breast cancer risk was especially pronounced among women with baseline Breast Tenderness.

  • Breast Tenderness and Breast cancer risk in the estrogen plus progestin and estrogen-alone women’s health initiative clinical trials
    Breast Cancer Research and Treatment, 2011
    Co-Authors: Carolyn J Crandall, Aaron K Aragaki, Anne Mctiernan, Garnet L Anderson, Jane A Cauley, Joann E Manson, Rowan T Chlebowski
    Abstract:

    The associations between Breast Tenderness during use of conjugated equine estrogen (CEE) therapy with or without medroxyprogesterone (MPA) therapy and subsequent Breast cancer risk are unknown. We analyzed data from the Women’s Health Initiative Estrogen plus Progestin (N = 16,608, 5.6 years intervention) and estrogen-alone (N = 10,739, 6.8 years intervention) clinical trials until trial close-out (Spring 2005). At baseline and annually, participants underwent mammography and clinical Breast exam. Self-reported Breast Tenderness was assessed at baseline and 12 months. Invasive Breast cancer was confirmed by medical record review. The risk of new-onset Breast Tenderness after 12 months was significantly higher among women assigned to active therapy than placebo (CEE-alone vs. placebo risk ratio [RR] 2.15, 95% confidence interval [CI] 1.97–2.35; CEE + MPA vs. placebo RR 3.07, 95% CI 2.85–3.30). CEE + MPA doubled the risk of invasive Breast cancer among women with baseline Breast Tenderness (hazard ratio [HR] 2.16, 95% CI 1.29–3.74), but had a smaller effect among women without baseline Breast Tenderness (HR 1.17; 95% CI 0.97–1.41). New-onset Breast Tenderness was associated with a higher risk of Breast cancer among women assigned to CEE + MPA (HR 1.33, 95% CI 1.02–1.72, P = 0.03), but not among women assigned to CEE-alone (HR 0.98, 95% CI 0.62–1.53). New-onset Breast Tenderness during use of CEE + MPA was associated with increased subsequent Breast cancer risk. The association of CEE + MPA therapy with increased Breast cancer risk was especially pronounced among women with baseline Breast Tenderness.

  • new onset Breast Tenderness after initiation of estrogen plus progestin therapy and Breast cancer risk
    JAMA Internal Medicine, 2009
    Co-Authors: Carolyn J Crandall, Aaron K Aragaki, Anne Mctiernan, Garnet L Anderson, Rowan T Chlebowski, Susan L Hendrix, Barbara B Cochrane, Lewis H Kuller, Jane A Cauley
    Abstract:

    Background Estrogen plus progestin therapy increases Breast cancer incidence and Breast Tenderness. Whether Breast Tenderness during estrogen plus progestin therapy is associated with Breast cancer risk is uncertain. Methods We analyzed data from the Women's Health Initiative Estrogen + Progestin Trial, which randomized postmenopausal women with an intact uterus to receive daily conjugated equine estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg (n = 8506), or placebo (n = 8102). At baseline and annually, participants underwent mammography and clinical Breast examination. Self-reported Breast Tenderness was assessed at baseline and at 12 months. The incidence of invasive Breast cancer was confirmed by medical record review (mean follow-up of 5.6 years). Results Of women without baseline Breast Tenderness (n = 14 538), significantly more assigned to receive conjugated equine estrogens plus medroxyprogesterone vs placebo experienced new-onset Breast Tenderness after 12 months (36.1% vs 11.8%, P P  = .02). In the placebo group, Breast cancer risk was not significantly associated with new-onset Breast Tenderness ( P  = .97). Conclusions New-onset Breast Tenderness during conjugated equine estrogens plus medroxyprogesterone therapy was associated with increased Breast cancer risk. The sensitivity and specificity of the association between Breast Tenderness and Breast cancer were similar in magnitude to those of the Gail model. Trial Registration clinicaltrials.gov Identifier: NCT00000611

Aaron K Aragaki - One of the best experts on this subject based on the ideXlab platform.

  • Breast Tenderness after initiation of conjugated equine estrogens and mammographic density change
    Breast Cancer Research and Treatment, 2012
    Co-Authors: Carolyn J Crandall, Aaron K Aragaki, Anne Mctiernan, Garnet L Anderson, Jean Wactawskiwende, Jane A Cauley, Joann E Manson, Rowan T Chlebowski
    Abstract:

    We examined the association between new-onset Breast Tenderness and change in mammographic density after initiation of conjugated equine estrogens (CEE). We analyzed baseline, year 1 and 2 data from 695 participants of the Women’s Health Initiative Estrogen + Progestin (daily CEE 0.625 mg + medroxyprogesterone acetate 2.5 mg [MPA] or placebo) and Estrogen-Alone (CEE 0.625 mg or placebo) trials who participated in the Mammogram Density Ancillary Study. Using multivariable repeated measures models, we analyzed the association between new-onset Breast Tenderness (i.e. absence of baseline Tenderness and presence of Tenderness at year 1 follow-up) and change from baseline in percent mammographic density. Active therapy increased the odds of new-onset Breast Tenderness (CEE + MPA vs. placebo risk ratio [RR] 3.01, 95% confidence interval [95% CI] 1.96–4.62; CEE vs. placebo RR 1.70, 95% CI 1.14–2.53). Among women assigned to CEE + MPA, mean increase in mammographic density was greater among participants reporting new-onset of Breast Tenderness than among participants without new-onset Breast Tenderness (11.3 vs. 3.9% at year 1, 9.4 vs. 3.2% at year 2, P < 0.001). Among women assigned to CEE alone, increase in mammographic density at year 1 follow-up was not significantly different in women with new-onset Breast Tenderness compared to women without new-onset Breast Tenderness (2.4 vs. 0.6% at year 1, 2.2 vs. 1.0% at year 2, P = 0.30). The new-onset of Breast Tenderness after initiation of CEE + MPA, but not CEE alone, is associated with greater increases in mammographic density.

  • Breast Tenderness and Breast cancer risk in the estrogen plus progestin and estrogen alone women s health initiative clinical trials
    Breast Cancer Research and Treatment, 2012
    Co-Authors: Carolyn J Crandall, Aaron K Aragaki, Anne Mctiernan, Garnet L Anderson, Jane A Cauley, Joann E Manson, Rowan T Chlebowski
    Abstract:

    The associations between Breast Tenderness during use of conjugated equine estrogen (CEE) therapy with or without medroxyprogesterone (MPA) therapy and subsequent Breast cancer risk are unknown. We analyzed data from the Women’s Health Initiative Estrogen plus Progestin (N = 16,608, 5.6 years intervention) and estrogen-alone (N = 10,739, 6.8 years intervention) clinical trials until trial close-out (Spring 2005). At baseline and annually, participants underwent mammography and clinical Breast exam. Self-reported Breast Tenderness was assessed at baseline and 12 months. Invasive Breast cancer was confirmed by medical record review. The risk of new-onset Breast Tenderness after 12 months was significantly higher among women assigned to active therapy than placebo (CEE-alone vs. placebo risk ratio [RR] 2.15, 95% confidence interval [CI] 1.97–2.35; CEE + MPA vs. placebo RR 3.07, 95% CI 2.85–3.30). CEE + MPA doubled the risk of invasive Breast cancer among women with baseline Breast Tenderness (hazard ratio [HR] 2.16, 95% CI 1.29–3.74), but had a smaller effect among women without baseline Breast Tenderness (HR 1.17; 95% CI 0.97–1.41). New-onset Breast Tenderness was associated with a higher risk of Breast cancer among women assigned to CEE + MPA (HR 1.33, 95% CI 1.02–1.72, P = 0.03), but not among women assigned to CEE-alone (HR 0.98, 95% CI 0.62–1.53). New-onset Breast Tenderness during use of CEE + MPA was associated with increased subsequent Breast cancer risk. The association of CEE + MPA therapy with increased Breast cancer risk was especially pronounced among women with baseline Breast Tenderness.

  • Breast Tenderness and Breast cancer risk in the estrogen plus progestin and estrogen-alone women’s health initiative clinical trials
    Breast Cancer Research and Treatment, 2011
    Co-Authors: Carolyn J Crandall, Aaron K Aragaki, Anne Mctiernan, Garnet L Anderson, Jane A Cauley, Joann E Manson, Rowan T Chlebowski
    Abstract:

    The associations between Breast Tenderness during use of conjugated equine estrogen (CEE) therapy with or without medroxyprogesterone (MPA) therapy and subsequent Breast cancer risk are unknown. We analyzed data from the Women’s Health Initiative Estrogen plus Progestin (N = 16,608, 5.6 years intervention) and estrogen-alone (N = 10,739, 6.8 years intervention) clinical trials until trial close-out (Spring 2005). At baseline and annually, participants underwent mammography and clinical Breast exam. Self-reported Breast Tenderness was assessed at baseline and 12 months. Invasive Breast cancer was confirmed by medical record review. The risk of new-onset Breast Tenderness after 12 months was significantly higher among women assigned to active therapy than placebo (CEE-alone vs. placebo risk ratio [RR] 2.15, 95% confidence interval [CI] 1.97–2.35; CEE + MPA vs. placebo RR 3.07, 95% CI 2.85–3.30). CEE + MPA doubled the risk of invasive Breast cancer among women with baseline Breast Tenderness (hazard ratio [HR] 2.16, 95% CI 1.29–3.74), but had a smaller effect among women without baseline Breast Tenderness (HR 1.17; 95% CI 0.97–1.41). New-onset Breast Tenderness was associated with a higher risk of Breast cancer among women assigned to CEE + MPA (HR 1.33, 95% CI 1.02–1.72, P = 0.03), but not among women assigned to CEE-alone (HR 0.98, 95% CI 0.62–1.53). New-onset Breast Tenderness during use of CEE + MPA was associated with increased subsequent Breast cancer risk. The association of CEE + MPA therapy with increased Breast cancer risk was especially pronounced among women with baseline Breast Tenderness.

  • menopausal symptom experience before and after stopping estrogen therapy in the women s health initiative randomized placebo controlled trial
    Menopause, 2010
    Co-Authors: Robert L Brunner, Aaron K Aragaki, Susan L Hendrix, Barbara B Cochrane, Vanessa M Barnabei, Margery Gass, Dorothy S Lane, Judith K Ockene, Nancy Fugate Woods, Shagufta Yasmeen
    Abstract:

    OBJECTIVE: The aim of this study was to assess vasomotor and other menopausal symptoms before starting estrogens or placebo, 1 year later, again at trial closure, and after stopping estrogens or placebo. The role of baseline symptoms and age was examined, as was the frequency and determinants of hormone use and symptom management strategies after discontinuing conjugated equine estrogens (CEE) or placebo. METHODS: Intent-to-treat analyses of 10,739 postmenopausal women before and 1 year after randomization to CEE or placebo at 40 clinical centers and a cohort analysis of participants (n = 3,496) who continued taking assigned study pills up to trial closure and completed symptom surveys shortly before (mean, 7.4 +/- 1.1 y from baseline) and after (mean, 306 +/- 55 d after trial closure) stopping pills were performed. Generalized linear regression modeled vasomotor symptoms, vaginal dryness, Breast Tenderness, pain/stiffness, and mood swings as a function of treatment assignment and baseline symptoms, before and after stopping study pills. RESULTS: Approximately one third of participants reported at least one moderate to severe symptom at baseline. Fewer symptoms were reported with increasing age, except joint pain/stiffness, which was similar among age groups. At 1 year, hot flashes, night sweats, and vaginal dryness were reduced by CEE, whereas Breast Tenderness was increased. Breast Tenderness was also significantly higher in the CEE group at trial closure. After stopping, vasomotor symptoms were reported by significantly more women who had reported symptoms at baseline, compared with those who had not, and by significantly more participants assigned to CEE (9.8%) versus placebo (3.2%); however, among women with no moderate or severe symptoms at baseline, more than five times as many reported hot flashes after stopping CEE (7.2%) versus placebo (1.5%). CONCLUSIONS: CEE significantly reduced vasomotor symptoms and vaginal dryness in women with baseline symptoms but increased Breast Tenderness. The likelihood of experiencing symptoms was significantly higher after stopping CEE than placebo regardless of baseline symptom status. These potential effects should be considered before initiating CEE to relieve menopausal symptoms.

  • new onset Breast Tenderness after initiation of estrogen plus progestin therapy and Breast cancer risk
    JAMA Internal Medicine, 2009
    Co-Authors: Carolyn J Crandall, Aaron K Aragaki, Anne Mctiernan, Garnet L Anderson, Rowan T Chlebowski, Susan L Hendrix, Barbara B Cochrane, Lewis H Kuller, Jane A Cauley
    Abstract:

    Background Estrogen plus progestin therapy increases Breast cancer incidence and Breast Tenderness. Whether Breast Tenderness during estrogen plus progestin therapy is associated with Breast cancer risk is uncertain. Methods We analyzed data from the Women's Health Initiative Estrogen + Progestin Trial, which randomized postmenopausal women with an intact uterus to receive daily conjugated equine estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg (n = 8506), or placebo (n = 8102). At baseline and annually, participants underwent mammography and clinical Breast examination. Self-reported Breast Tenderness was assessed at baseline and at 12 months. The incidence of invasive Breast cancer was confirmed by medical record review (mean follow-up of 5.6 years). Results Of women without baseline Breast Tenderness (n = 14 538), significantly more assigned to receive conjugated equine estrogens plus medroxyprogesterone vs placebo experienced new-onset Breast Tenderness after 12 months (36.1% vs 11.8%, P P  = .02). In the placebo group, Breast cancer risk was not significantly associated with new-onset Breast Tenderness ( P  = .97). Conclusions New-onset Breast Tenderness during conjugated equine estrogens plus medroxyprogesterone therapy was associated with increased Breast cancer risk. The sensitivity and specificity of the association between Breast Tenderness and Breast cancer were similar in magnitude to those of the Gail model. Trial Registration clinicaltrials.gov Identifier: NCT00000611

Carolyn J Crandall - One of the best experts on this subject based on the ideXlab platform.

  • Breast Tenderness after initiation of conjugated equine estrogens and mammographic density change
    Breast Cancer Research and Treatment, 2012
    Co-Authors: Carolyn J Crandall, Aaron K Aragaki, Anne Mctiernan, Garnet L Anderson, Jean Wactawskiwende, Jane A Cauley, Joann E Manson, Rowan T Chlebowski
    Abstract:

    We examined the association between new-onset Breast Tenderness and change in mammographic density after initiation of conjugated equine estrogens (CEE). We analyzed baseline, year 1 and 2 data from 695 participants of the Women’s Health Initiative Estrogen + Progestin (daily CEE 0.625 mg + medroxyprogesterone acetate 2.5 mg [MPA] or placebo) and Estrogen-Alone (CEE 0.625 mg or placebo) trials who participated in the Mammogram Density Ancillary Study. Using multivariable repeated measures models, we analyzed the association between new-onset Breast Tenderness (i.e. absence of baseline Tenderness and presence of Tenderness at year 1 follow-up) and change from baseline in percent mammographic density. Active therapy increased the odds of new-onset Breast Tenderness (CEE + MPA vs. placebo risk ratio [RR] 3.01, 95% confidence interval [95% CI] 1.96–4.62; CEE vs. placebo RR 1.70, 95% CI 1.14–2.53). Among women assigned to CEE + MPA, mean increase in mammographic density was greater among participants reporting new-onset of Breast Tenderness than among participants without new-onset Breast Tenderness (11.3 vs. 3.9% at year 1, 9.4 vs. 3.2% at year 2, P < 0.001). Among women assigned to CEE alone, increase in mammographic density at year 1 follow-up was not significantly different in women with new-onset Breast Tenderness compared to women without new-onset Breast Tenderness (2.4 vs. 0.6% at year 1, 2.2 vs. 1.0% at year 2, P = 0.30). The new-onset of Breast Tenderness after initiation of CEE + MPA, but not CEE alone, is associated with greater increases in mammographic density.

  • Breast Tenderness and Breast cancer risk in the estrogen plus progestin and estrogen alone women s health initiative clinical trials
    Breast Cancer Research and Treatment, 2012
    Co-Authors: Carolyn J Crandall, Aaron K Aragaki, Anne Mctiernan, Garnet L Anderson, Jane A Cauley, Joann E Manson, Rowan T Chlebowski
    Abstract:

    The associations between Breast Tenderness during use of conjugated equine estrogen (CEE) therapy with or without medroxyprogesterone (MPA) therapy and subsequent Breast cancer risk are unknown. We analyzed data from the Women’s Health Initiative Estrogen plus Progestin (N = 16,608, 5.6 years intervention) and estrogen-alone (N = 10,739, 6.8 years intervention) clinical trials until trial close-out (Spring 2005). At baseline and annually, participants underwent mammography and clinical Breast exam. Self-reported Breast Tenderness was assessed at baseline and 12 months. Invasive Breast cancer was confirmed by medical record review. The risk of new-onset Breast Tenderness after 12 months was significantly higher among women assigned to active therapy than placebo (CEE-alone vs. placebo risk ratio [RR] 2.15, 95% confidence interval [CI] 1.97–2.35; CEE + MPA vs. placebo RR 3.07, 95% CI 2.85–3.30). CEE + MPA doubled the risk of invasive Breast cancer among women with baseline Breast Tenderness (hazard ratio [HR] 2.16, 95% CI 1.29–3.74), but had a smaller effect among women without baseline Breast Tenderness (HR 1.17; 95% CI 0.97–1.41). New-onset Breast Tenderness was associated with a higher risk of Breast cancer among women assigned to CEE + MPA (HR 1.33, 95% CI 1.02–1.72, P = 0.03), but not among women assigned to CEE-alone (HR 0.98, 95% CI 0.62–1.53). New-onset Breast Tenderness during use of CEE + MPA was associated with increased subsequent Breast cancer risk. The association of CEE + MPA therapy with increased Breast cancer risk was especially pronounced among women with baseline Breast Tenderness.

  • Breast Tenderness and Breast cancer risk in the estrogen plus progestin and estrogen-alone women’s health initiative clinical trials
    Breast Cancer Research and Treatment, 2011
    Co-Authors: Carolyn J Crandall, Aaron K Aragaki, Anne Mctiernan, Garnet L Anderson, Jane A Cauley, Joann E Manson, Rowan T Chlebowski
    Abstract:

    The associations between Breast Tenderness during use of conjugated equine estrogen (CEE) therapy with or without medroxyprogesterone (MPA) therapy and subsequent Breast cancer risk are unknown. We analyzed data from the Women’s Health Initiative Estrogen plus Progestin (N = 16,608, 5.6 years intervention) and estrogen-alone (N = 10,739, 6.8 years intervention) clinical trials until trial close-out (Spring 2005). At baseline and annually, participants underwent mammography and clinical Breast exam. Self-reported Breast Tenderness was assessed at baseline and 12 months. Invasive Breast cancer was confirmed by medical record review. The risk of new-onset Breast Tenderness after 12 months was significantly higher among women assigned to active therapy than placebo (CEE-alone vs. placebo risk ratio [RR] 2.15, 95% confidence interval [CI] 1.97–2.35; CEE + MPA vs. placebo RR 3.07, 95% CI 2.85–3.30). CEE + MPA doubled the risk of invasive Breast cancer among women with baseline Breast Tenderness (hazard ratio [HR] 2.16, 95% CI 1.29–3.74), but had a smaller effect among women without baseline Breast Tenderness (HR 1.17; 95% CI 0.97–1.41). New-onset Breast Tenderness was associated with a higher risk of Breast cancer among women assigned to CEE + MPA (HR 1.33, 95% CI 1.02–1.72, P = 0.03), but not among women assigned to CEE-alone (HR 0.98, 95% CI 0.62–1.53). New-onset Breast Tenderness during use of CEE + MPA was associated with increased subsequent Breast cancer risk. The association of CEE + MPA therapy with increased Breast cancer risk was especially pronounced among women with baseline Breast Tenderness.

  • new onset Breast Tenderness after initiation of estrogen plus progestin therapy and Breast cancer risk
    JAMA Internal Medicine, 2009
    Co-Authors: Carolyn J Crandall, Aaron K Aragaki, Anne Mctiernan, Garnet L Anderson, Rowan T Chlebowski, Susan L Hendrix, Barbara B Cochrane, Lewis H Kuller, Jane A Cauley
    Abstract:

    Background Estrogen plus progestin therapy increases Breast cancer incidence and Breast Tenderness. Whether Breast Tenderness during estrogen plus progestin therapy is associated with Breast cancer risk is uncertain. Methods We analyzed data from the Women's Health Initiative Estrogen + Progestin Trial, which randomized postmenopausal women with an intact uterus to receive daily conjugated equine estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg (n = 8506), or placebo (n = 8102). At baseline and annually, participants underwent mammography and clinical Breast examination. Self-reported Breast Tenderness was assessed at baseline and at 12 months. The incidence of invasive Breast cancer was confirmed by medical record review (mean follow-up of 5.6 years). Results Of women without baseline Breast Tenderness (n = 14 538), significantly more assigned to receive conjugated equine estrogens plus medroxyprogesterone vs placebo experienced new-onset Breast Tenderness after 12 months (36.1% vs 11.8%, P P  = .02). In the placebo group, Breast cancer risk was not significantly associated with new-onset Breast Tenderness ( P  = .97). Conclusions New-onset Breast Tenderness during conjugated equine estrogens plus medroxyprogesterone therapy was associated with increased Breast cancer risk. The sensitivity and specificity of the association between Breast Tenderness and Breast cancer were similar in magnitude to those of the Gail model. Trial Registration clinicaltrials.gov Identifier: NCT00000611

Jane A Cauley - One of the best experts on this subject based on the ideXlab platform.

  • Breast Tenderness after initiation of conjugated equine estrogens and mammographic density change
    Breast Cancer Research and Treatment, 2012
    Co-Authors: Carolyn J Crandall, Aaron K Aragaki, Anne Mctiernan, Garnet L Anderson, Jean Wactawskiwende, Jane A Cauley, Joann E Manson, Rowan T Chlebowski
    Abstract:

    We examined the association between new-onset Breast Tenderness and change in mammographic density after initiation of conjugated equine estrogens (CEE). We analyzed baseline, year 1 and 2 data from 695 participants of the Women’s Health Initiative Estrogen + Progestin (daily CEE 0.625 mg + medroxyprogesterone acetate 2.5 mg [MPA] or placebo) and Estrogen-Alone (CEE 0.625 mg or placebo) trials who participated in the Mammogram Density Ancillary Study. Using multivariable repeated measures models, we analyzed the association between new-onset Breast Tenderness (i.e. absence of baseline Tenderness and presence of Tenderness at year 1 follow-up) and change from baseline in percent mammographic density. Active therapy increased the odds of new-onset Breast Tenderness (CEE + MPA vs. placebo risk ratio [RR] 3.01, 95% confidence interval [95% CI] 1.96–4.62; CEE vs. placebo RR 1.70, 95% CI 1.14–2.53). Among women assigned to CEE + MPA, mean increase in mammographic density was greater among participants reporting new-onset of Breast Tenderness than among participants without new-onset Breast Tenderness (11.3 vs. 3.9% at year 1, 9.4 vs. 3.2% at year 2, P < 0.001). Among women assigned to CEE alone, increase in mammographic density at year 1 follow-up was not significantly different in women with new-onset Breast Tenderness compared to women without new-onset Breast Tenderness (2.4 vs. 0.6% at year 1, 2.2 vs. 1.0% at year 2, P = 0.30). The new-onset of Breast Tenderness after initiation of CEE + MPA, but not CEE alone, is associated with greater increases in mammographic density.

  • Breast Tenderness and Breast cancer risk in the estrogen plus progestin and estrogen alone women s health initiative clinical trials
    Breast Cancer Research and Treatment, 2012
    Co-Authors: Carolyn J Crandall, Aaron K Aragaki, Anne Mctiernan, Garnet L Anderson, Jane A Cauley, Joann E Manson, Rowan T Chlebowski
    Abstract:

    The associations between Breast Tenderness during use of conjugated equine estrogen (CEE) therapy with or without medroxyprogesterone (MPA) therapy and subsequent Breast cancer risk are unknown. We analyzed data from the Women’s Health Initiative Estrogen plus Progestin (N = 16,608, 5.6 years intervention) and estrogen-alone (N = 10,739, 6.8 years intervention) clinical trials until trial close-out (Spring 2005). At baseline and annually, participants underwent mammography and clinical Breast exam. Self-reported Breast Tenderness was assessed at baseline and 12 months. Invasive Breast cancer was confirmed by medical record review. The risk of new-onset Breast Tenderness after 12 months was significantly higher among women assigned to active therapy than placebo (CEE-alone vs. placebo risk ratio [RR] 2.15, 95% confidence interval [CI] 1.97–2.35; CEE + MPA vs. placebo RR 3.07, 95% CI 2.85–3.30). CEE + MPA doubled the risk of invasive Breast cancer among women with baseline Breast Tenderness (hazard ratio [HR] 2.16, 95% CI 1.29–3.74), but had a smaller effect among women without baseline Breast Tenderness (HR 1.17; 95% CI 0.97–1.41). New-onset Breast Tenderness was associated with a higher risk of Breast cancer among women assigned to CEE + MPA (HR 1.33, 95% CI 1.02–1.72, P = 0.03), but not among women assigned to CEE-alone (HR 0.98, 95% CI 0.62–1.53). New-onset Breast Tenderness during use of CEE + MPA was associated with increased subsequent Breast cancer risk. The association of CEE + MPA therapy with increased Breast cancer risk was especially pronounced among women with baseline Breast Tenderness.

  • Breast Tenderness and Breast cancer risk in the estrogen plus progestin and estrogen-alone women’s health initiative clinical trials
    Breast Cancer Research and Treatment, 2011
    Co-Authors: Carolyn J Crandall, Aaron K Aragaki, Anne Mctiernan, Garnet L Anderson, Jane A Cauley, Joann E Manson, Rowan T Chlebowski
    Abstract:

    The associations between Breast Tenderness during use of conjugated equine estrogen (CEE) therapy with or without medroxyprogesterone (MPA) therapy and subsequent Breast cancer risk are unknown. We analyzed data from the Women’s Health Initiative Estrogen plus Progestin (N = 16,608, 5.6 years intervention) and estrogen-alone (N = 10,739, 6.8 years intervention) clinical trials until trial close-out (Spring 2005). At baseline and annually, participants underwent mammography and clinical Breast exam. Self-reported Breast Tenderness was assessed at baseline and 12 months. Invasive Breast cancer was confirmed by medical record review. The risk of new-onset Breast Tenderness after 12 months was significantly higher among women assigned to active therapy than placebo (CEE-alone vs. placebo risk ratio [RR] 2.15, 95% confidence interval [CI] 1.97–2.35; CEE + MPA vs. placebo RR 3.07, 95% CI 2.85–3.30). CEE + MPA doubled the risk of invasive Breast cancer among women with baseline Breast Tenderness (hazard ratio [HR] 2.16, 95% CI 1.29–3.74), but had a smaller effect among women without baseline Breast Tenderness (HR 1.17; 95% CI 0.97–1.41). New-onset Breast Tenderness was associated with a higher risk of Breast cancer among women assigned to CEE + MPA (HR 1.33, 95% CI 1.02–1.72, P = 0.03), but not among women assigned to CEE-alone (HR 0.98, 95% CI 0.62–1.53). New-onset Breast Tenderness during use of CEE + MPA was associated with increased subsequent Breast cancer risk. The association of CEE + MPA therapy with increased Breast cancer risk was especially pronounced among women with baseline Breast Tenderness.

  • new onset Breast Tenderness after initiation of estrogen plus progestin therapy and Breast cancer risk
    JAMA Internal Medicine, 2009
    Co-Authors: Carolyn J Crandall, Aaron K Aragaki, Anne Mctiernan, Garnet L Anderson, Rowan T Chlebowski, Susan L Hendrix, Barbara B Cochrane, Lewis H Kuller, Jane A Cauley
    Abstract:

    Background Estrogen plus progestin therapy increases Breast cancer incidence and Breast Tenderness. Whether Breast Tenderness during estrogen plus progestin therapy is associated with Breast cancer risk is uncertain. Methods We analyzed data from the Women's Health Initiative Estrogen + Progestin Trial, which randomized postmenopausal women with an intact uterus to receive daily conjugated equine estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg (n = 8506), or placebo (n = 8102). At baseline and annually, participants underwent mammography and clinical Breast examination. Self-reported Breast Tenderness was assessed at baseline and at 12 months. The incidence of invasive Breast cancer was confirmed by medical record review (mean follow-up of 5.6 years). Results Of women without baseline Breast Tenderness (n = 14 538), significantly more assigned to receive conjugated equine estrogens plus medroxyprogesterone vs placebo experienced new-onset Breast Tenderness after 12 months (36.1% vs 11.8%, P P  = .02). In the placebo group, Breast cancer risk was not significantly associated with new-onset Breast Tenderness ( P  = .97). Conclusions New-onset Breast Tenderness during conjugated equine estrogens plus medroxyprogesterone therapy was associated with increased Breast cancer risk. The sensitivity and specificity of the association between Breast Tenderness and Breast cancer were similar in magnitude to those of the Gail model. Trial Registration clinicaltrials.gov Identifier: NCT00000611

Garnet L Anderson - One of the best experts on this subject based on the ideXlab platform.

  • Breast Tenderness after initiation of conjugated equine estrogens and mammographic density change
    Breast Cancer Research and Treatment, 2012
    Co-Authors: Carolyn J Crandall, Aaron K Aragaki, Anne Mctiernan, Garnet L Anderson, Jean Wactawskiwende, Jane A Cauley, Joann E Manson, Rowan T Chlebowski
    Abstract:

    We examined the association between new-onset Breast Tenderness and change in mammographic density after initiation of conjugated equine estrogens (CEE). We analyzed baseline, year 1 and 2 data from 695 participants of the Women’s Health Initiative Estrogen + Progestin (daily CEE 0.625 mg + medroxyprogesterone acetate 2.5 mg [MPA] or placebo) and Estrogen-Alone (CEE 0.625 mg or placebo) trials who participated in the Mammogram Density Ancillary Study. Using multivariable repeated measures models, we analyzed the association between new-onset Breast Tenderness (i.e. absence of baseline Tenderness and presence of Tenderness at year 1 follow-up) and change from baseline in percent mammographic density. Active therapy increased the odds of new-onset Breast Tenderness (CEE + MPA vs. placebo risk ratio [RR] 3.01, 95% confidence interval [95% CI] 1.96–4.62; CEE vs. placebo RR 1.70, 95% CI 1.14–2.53). Among women assigned to CEE + MPA, mean increase in mammographic density was greater among participants reporting new-onset of Breast Tenderness than among participants without new-onset Breast Tenderness (11.3 vs. 3.9% at year 1, 9.4 vs. 3.2% at year 2, P < 0.001). Among women assigned to CEE alone, increase in mammographic density at year 1 follow-up was not significantly different in women with new-onset Breast Tenderness compared to women without new-onset Breast Tenderness (2.4 vs. 0.6% at year 1, 2.2 vs. 1.0% at year 2, P = 0.30). The new-onset of Breast Tenderness after initiation of CEE + MPA, but not CEE alone, is associated with greater increases in mammographic density.

  • Breast Tenderness and Breast cancer risk in the estrogen plus progestin and estrogen alone women s health initiative clinical trials
    Breast Cancer Research and Treatment, 2012
    Co-Authors: Carolyn J Crandall, Aaron K Aragaki, Anne Mctiernan, Garnet L Anderson, Jane A Cauley, Joann E Manson, Rowan T Chlebowski
    Abstract:

    The associations between Breast Tenderness during use of conjugated equine estrogen (CEE) therapy with or without medroxyprogesterone (MPA) therapy and subsequent Breast cancer risk are unknown. We analyzed data from the Women’s Health Initiative Estrogen plus Progestin (N = 16,608, 5.6 years intervention) and estrogen-alone (N = 10,739, 6.8 years intervention) clinical trials until trial close-out (Spring 2005). At baseline and annually, participants underwent mammography and clinical Breast exam. Self-reported Breast Tenderness was assessed at baseline and 12 months. Invasive Breast cancer was confirmed by medical record review. The risk of new-onset Breast Tenderness after 12 months was significantly higher among women assigned to active therapy than placebo (CEE-alone vs. placebo risk ratio [RR] 2.15, 95% confidence interval [CI] 1.97–2.35; CEE + MPA vs. placebo RR 3.07, 95% CI 2.85–3.30). CEE + MPA doubled the risk of invasive Breast cancer among women with baseline Breast Tenderness (hazard ratio [HR] 2.16, 95% CI 1.29–3.74), but had a smaller effect among women without baseline Breast Tenderness (HR 1.17; 95% CI 0.97–1.41). New-onset Breast Tenderness was associated with a higher risk of Breast cancer among women assigned to CEE + MPA (HR 1.33, 95% CI 1.02–1.72, P = 0.03), but not among women assigned to CEE-alone (HR 0.98, 95% CI 0.62–1.53). New-onset Breast Tenderness during use of CEE + MPA was associated with increased subsequent Breast cancer risk. The association of CEE + MPA therapy with increased Breast cancer risk was especially pronounced among women with baseline Breast Tenderness.

  • Breast Tenderness and Breast cancer risk in the estrogen plus progestin and estrogen-alone women’s health initiative clinical trials
    Breast Cancer Research and Treatment, 2011
    Co-Authors: Carolyn J Crandall, Aaron K Aragaki, Anne Mctiernan, Garnet L Anderson, Jane A Cauley, Joann E Manson, Rowan T Chlebowski
    Abstract:

    The associations between Breast Tenderness during use of conjugated equine estrogen (CEE) therapy with or without medroxyprogesterone (MPA) therapy and subsequent Breast cancer risk are unknown. We analyzed data from the Women’s Health Initiative Estrogen plus Progestin (N = 16,608, 5.6 years intervention) and estrogen-alone (N = 10,739, 6.8 years intervention) clinical trials until trial close-out (Spring 2005). At baseline and annually, participants underwent mammography and clinical Breast exam. Self-reported Breast Tenderness was assessed at baseline and 12 months. Invasive Breast cancer was confirmed by medical record review. The risk of new-onset Breast Tenderness after 12 months was significantly higher among women assigned to active therapy than placebo (CEE-alone vs. placebo risk ratio [RR] 2.15, 95% confidence interval [CI] 1.97–2.35; CEE + MPA vs. placebo RR 3.07, 95% CI 2.85–3.30). CEE + MPA doubled the risk of invasive Breast cancer among women with baseline Breast Tenderness (hazard ratio [HR] 2.16, 95% CI 1.29–3.74), but had a smaller effect among women without baseline Breast Tenderness (HR 1.17; 95% CI 0.97–1.41). New-onset Breast Tenderness was associated with a higher risk of Breast cancer among women assigned to CEE + MPA (HR 1.33, 95% CI 1.02–1.72, P = 0.03), but not among women assigned to CEE-alone (HR 0.98, 95% CI 0.62–1.53). New-onset Breast Tenderness during use of CEE + MPA was associated with increased subsequent Breast cancer risk. The association of CEE + MPA therapy with increased Breast cancer risk was especially pronounced among women with baseline Breast Tenderness.

  • new onset Breast Tenderness after initiation of estrogen plus progestin therapy and Breast cancer risk
    JAMA Internal Medicine, 2009
    Co-Authors: Carolyn J Crandall, Aaron K Aragaki, Anne Mctiernan, Garnet L Anderson, Rowan T Chlebowski, Susan L Hendrix, Barbara B Cochrane, Lewis H Kuller, Jane A Cauley
    Abstract:

    Background Estrogen plus progestin therapy increases Breast cancer incidence and Breast Tenderness. Whether Breast Tenderness during estrogen plus progestin therapy is associated with Breast cancer risk is uncertain. Methods We analyzed data from the Women's Health Initiative Estrogen + Progestin Trial, which randomized postmenopausal women with an intact uterus to receive daily conjugated equine estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg (n = 8506), or placebo (n = 8102). At baseline and annually, participants underwent mammography and clinical Breast examination. Self-reported Breast Tenderness was assessed at baseline and at 12 months. The incidence of invasive Breast cancer was confirmed by medical record review (mean follow-up of 5.6 years). Results Of women without baseline Breast Tenderness (n = 14 538), significantly more assigned to receive conjugated equine estrogens plus medroxyprogesterone vs placebo experienced new-onset Breast Tenderness after 12 months (36.1% vs 11.8%, P P  = .02). In the placebo group, Breast cancer risk was not significantly associated with new-onset Breast Tenderness ( P  = .97). Conclusions New-onset Breast Tenderness during conjugated equine estrogens plus medroxyprogesterone therapy was associated with increased Breast cancer risk. The sensitivity and specificity of the association between Breast Tenderness and Breast cancer were similar in magnitude to those of the Gail model. Trial Registration clinicaltrials.gov Identifier: NCT00000611